Trials / Active Not Recruiting
Active Not RecruitingNCT03185039
Predictive Impact of MMP2 and MMP9 Levels for Patients With Metastatic Kidney Cancer Treated With Anti-angiogenic Agents
Study of the Predictive Impact of MMP2 and MMP9 Levels for Patients With Metastatic Kidney Cancer Treated With Anti-angiogenic Agents Compared to Patients Not Treated With Antiangiogenic (Localized Kidney Cancer and Oligometastatic)
- Status
- Active Not Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Institut Paoli-Calmettes · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Prospective research of Matrix Metalloproteinases (MMP) 2 and 9 as predictive biomarkers in metastatic kidney cancer patients treated with 2 anti angiogenic agents (Sunitinib or Pazopanib).
Detailed description
The objective is to analyze the predictive impact of circulating MMP2 and MMP9 on the progression-free survival of patients with metastatic kidney cancer treated with anti-angiogenic agents (Sunitinib or Pazopanib) in comparison with two untreated cohorts (localized or oligometastatic cancer). Prospective monocenter, open-label study In the frame of disease management blood samples will be collected at different times of follow-up regarding disease status (localized, oligometastatic and metastatic) and tissue samples will be collected for patients scheduled for surgery.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Blood and tumor samples | Blood and tumor samples |
Timeline
- Start date
- 2017-05-29
- Primary completion
- 2026-12-19
- Completion
- 2026-12-19
- First posted
- 2017-06-14
- Last updated
- 2026-03-19
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT03185039. Inclusion in this directory is not an endorsement.